Videos

At the 2026 ASCP Annual Meeting, Eric Konofal, MD, PhD, argued that sleep assessment should become a routine part of ADHD evaluation and treatment.

A phase 2b/3 trial of Forvisirvat in major depressive disorder is investigating potential sex-specific antidepressant effects in women.

Expert psychiatrists share new ASCP deprescribing guidance, tackling overprescribing, primary-care challenges, and practical tapering strategies to improve safer, patient-centered mental health care.

Award-winning psychiatrist Steven Moffic, MD, urges psychiatry to elevate social, spiritual, and moral care, tackling burnout, tech, and ecological ethics.

Experts share strategies to boost schizophrenia adherence—family partnership, early engagement, and newer antipsychotics to improve long‑term function.

Clinicians explore transdiagnostic anhedonia—reward learning, loneliness, and digital rewards—offering practical ideas to personalize treatment.

New real-world data in obese, antidepressant-naive patients with MDD shows bupropion edging SSRIs on remission, though rates stay low.

Investigational depression drugs target SIRT6 epigenetics, histamine H3, and AMPA.

The ASCp meeting spotlights a fast-acting psychedelic for postpartum depression, vasopressin-targeting drugs, and ketamine’s promise for Parkinson symptoms.

Collaborative care boosts PTSD and opioid treatment together.

Study finds most bipolar depression outpatients have multiple comorbidities; many seek care, but substance use and phobias often go untreated.

Experts discuss ketamine safety, monitoring, neurotoxicity concerns, and key considerations for psychiatrists treating depression at the ASCP Annual Meeting.

APA session probes ADHD stimulant prescribing, contrasts population studies with RCTs, and explores education and brain effects.

Researchers at the ASCP Annual Meeting reported on how impaired brain insulin signaling may predict worsening depression severity and the links between metabolism and mood.

New trials find collaborative care improves OUD and mental health outcomes.

ASCP 2026 leaders share practical ways to engage patients in acute psychosis—active listening, noncollusive language, and rapport before assessment.

AI adoption in psychiatry and emerging psychedelic therapies are among the most anticipated topics at ASCP 2026, according to Benjamin Brody, MD.

David W. Goodman, MD, discusses the new ASCP consensus recommendations on when clinicians should consider deprescribing stimulants as part of good ADHD care.

Curiosity, rapport, and understanding lived experience can strengthen schizophrenia care and treatment engagement, according to Tracy Hicks, DNP.

John J. Miller, MD, Psychiatric Times editor in chief, looks forward to learning and sharing the late-breaking science, expert interviews, and new podcast conversations in psychopharmacology.

Psychiatrist Gus Alva highlights new depression therapies, neuromodulation, and why screening for bipolar disorder prevents antidepressant harm.

Learn why insomnia and daytime sleepiness signal psychiatric risk, and how screening for apnea, delayed phase, and fatigue sharpens treatment.

Explore why sexual health matters after 65 and how clinician comfort boosts disclosure.

Unpack gaming, gambling, social media, and exercise addiction, spotlighting comorbid anxiety, withdrawal signs, and harm-reduction treatment.

Digital gaming, gambling, and AI reliance drive emerging behavioral addictions, affecting mood and cognition.

Olanzapine-samidorphan keeps olanzapine efficacy yet limits weight gain, boosts negative symptoms, and cuts ER visits in real-world care.

Explore practical ways psychiatrists address sexual side effects and adjust medication for older adults.

New data from 245K clinicians reveals therapy access roadblocks—and how online scheduling helps patients find available care faster.

How ketamine enhances psychotherapy—and what new psilocybin studies suggest about broader health effects.